<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775020</url>
  </required_header>
  <id_info>
    <org_study_id>MEC03-139.5</org_study_id>
    <nct_id>NCT01775020</nct_id>
  </id_info>
  <brief_title>Dose-response Study of Arginine Supplementation in Severe Sepsis</brief_title>
  <official_title>Arginine and Nitric Oxide (NO) Metabolism in Sepsis; Dose-response Study on the Effect of L-arginine Supplementation on NO Metabolism and Gastric Perfusion in Severe Septic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Medical Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot data in patients and data from pig studies indicate that arginine-NO metabolism is
      impaired in sepsis with changes in splanchnic metabolism and function, and reduced survival
      at low nitrate levels. Prolonged intravenous supplementation of L-arginine proved effective
      in pigs for increasing NO production, restoring gut function, and inhibiting an increase in
      pulmonary arterial pressure, without any deleterious systemic side effects. Prolonged
      intravenous L-arginine supplementation could therefore be useful in septic ICU patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nitric oxide synthesis</measure>
    <time_frame>8 hours</time_frame>
    <description>Nitric oxide synthesis at step-wise increasing doses of L-arginine infusion. Following a 2h baseline measurements, 3 stepwise increasing arginine doses each provided for 2h will be tested for the effect on NO synthesis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemodynamics</measure>
    <time_frame>8 hours</time_frame>
    <description>Mean arterial pressure (MAP), pulmonary arterial pressure (PAP), cardiac output (CO), cardiac index (CI), heart rate (HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameters</measure>
    <time_frame>8 hours</time_frame>
    <description>Blood gasses, electrolytes, glucose, insulin, amino acids, whole body protein and arginine metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastric perfusion</measure>
    <time_frame>8 hours</time_frame>
    <description>Regional (gastric) CO2 production measured with tonometry (PrCO2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-arginine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <arm_group_label>L-arginine</arm_group_label>
    <other_name>L-arginine-HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from close relative

          -  Age &gt; 18 years

          -  Patient meets the general criteria for severe sepsis or septic shock, diagnosed less
             than 48 h prior to study inclusion (see appendix A; in Dutch).

          -  Patient must be relatively hemodynamically stable, defined as stable blood pressure
             (variation in mean arterial pressure &lt;15 mm Hg) during 2 h without necessity of
             increasing the vasopressor dose, inotropic support or rate of fluid administration.

          -  Systemic and pulmonary arterial catheters in place with continuous pressure
             monitoring.

          -  Patients in whom the clinician is prepared to provide full life support during the
             duration of the study, including a life expectance of &gt; 24 h.

        Exclusion Criteria:

          -  Shock due to any cause other than sepsis (e.g. drug reaction or drug overdose,
             pulmonary embolus, burn injury etc.)

          -  Corticosteroid use (prolonged intake of &gt; 1mg/kg daily or intake of &gt; 70 mg/day for 7
             consecutive days within 1 month preceding the study)

          -  Liver cirrhosis

          -  Chronic pancreatitis

          -  Diabetes mellitus type I

          -  Metastases, haematological malignancies or chemotherapy

          -  Patients on dialysis (CVVH or other)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas E Deutz, MD PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <reference>
    <citation>Luiking YC, Poeze M, Ramsay G, Deutz NE. Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production. Am J Clin Nutr. 2009 Jan;89(1):142-52. doi: 10.3945/ajcn.2007.25765. Epub 2008 Dec 3.</citation>
    <PMID>19056593</PMID>
  </reference>
  <reference>
    <citation>Poeze M, Bruins MJ, Kessels F, Luiking YC, Lamers WH, Deutz NE. Effects of L-arginine pretreatment on nitric oxide metabolism and hepatosplanchnic perfusion during porcine endotoxemia. Am J Clin Nutr. 2011 Jun;93(6):1237-47. doi: 10.3945/ajcn.110.007237. Epub 2011 Apr 20.</citation>
    <PMID>21508091</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

